David Mott
New Enterprise Associates General Partner
Your Intro Paths to David Mott
Signal uses Gmail to reveal intro paths. Email content is never read.
Sign in with Google →Find David Mott on
cb
investment range
$200k - $40.0m
sweet spot
$10.0m
David Mott's Past Investments (13)
| Company | Deal Type | Amount | Date | |
|---|---|---|---|---|
| Nightstar Therapeutics | Series C | $45M | Jun 2017 | |
| Ardelyx | Post-IPO Equity | $110M | Jul 2016 | |
| Nightstar Therapeutics | Series B | $35M (Lead) | Nov 2015 | |
| Clementia Pharmaceuticals | Venture Round | $60M (Lead) | Jun 2015 | |
| Ardelyx | Post-IPO Equity | $77.8M (Lead) | Jun 2015 | |
| Adaptimmune | Series A | $104M (Lead) | Sep 2014 | |
| Cydan | Venture Round | $10M | Oct 2013 | |
| Edimer Pharmaceuticals | Series B | $18M (Lead) | Jul 2013 | |
| Cydan | Venture Round | $16M (Lead) | Apr 2013 | |
| Prosensa | Venture Round | €23M (Lead) | Jan 2012 |
David Mott's Media
No media found for David Mott. Add it now.
Your Intro Paths to David Mott
Signal uses Gmail to reveal intro paths. Email content is never read.
Sign in with Google →Find David Mott on
cb